Since Drp1 is already emerging as a chemotherapeutic target [47], our current findings strongly encourage detailed investigation of the mechanisms underlying the crosstalk between Drp1 and cell cycle in various tumor types. This evidence concerns the gene DNM1L and neoplasm.